Arcturus Therapeutics Holdings (ARCT) EBITDA (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of EBITDA data on file, last reported at -$28.9 million in Q1 2026.

• Quarterly EBITDA fell 71.94% year-over-year to -$28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$88.4 million (down 7.65% YoY) and the FY2025 annual result came in at -$76.3 million, up 20.29% from the prior year.
• EBITDA advanced to -$28.9 million in Q1 2026, from -$31.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $121.5 million in Q4 2022 to a low of -$55.4 million in Q2 2023.
• A 5-year average of -$15.7 million and a median of -$21.1 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA jumped 422.62% — and 2024, when it tumbled 306.11%.
• Tracing ARCT's EBITDA over 5 years: stood at $121.5 million in 2022, then tumbled by 115.04% to -$18.3 million in 2023, then tumbled by 82.76% to -$33.4 million in 2024, then grew by 6.25% to -$31.3 million in 2025, then gained by 7.59% to -$28.9 million in 2026.
• The last three EBITDA figures came in at -$28.9 million (Q1 2026), -$31.3 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.